Arcturus Therapeutics (NASDAQ: ARCT) — Company Overview, News & Financial Data
Arcturus Therapeutics develops RNA therapeutics for rare diseases and vaccines, focusing on innovative solutions for unmet medical needs.
Arcturus Therapeutics
Arcturus Therapeutics (NASDAQ:ARCT) is a biotechnology company focused on the discovery, development, and commercialization of RNA therapeutics for rare diseases and vaccines. The company leverages its proprietary lipid nanoparticle delivery system and RNA platforms to develop novel therapeutics. Arcturus’s projects include treatments for cystic fibrosis, liver diseases, and a diverse pipeline of mRNA vaccines against infectious diseases. The objective of Arcturus is to harness the potential of RNA therapies to address unmet medical needs and improve patient outcomes through its innovative research and development efforts.
Snapshot
Operations
Products and/or services of Arcturus Therapeutics
- LUNAR-COV19 (ARCT-021), a vaccine candidate designed to prevent COVID-19 using self-amplifying mRNA technology.
- LUNAR-OTC, aiming to treat Ornithine Transcarbamylase (OTC) Deficiency by delivering OTC mRNA to liver cells.
- LUNAR-CF, focused on treating Cystic Fibrosis through the delivery of mRNA to the lungs to enable CFTR protein production.
- ARCT-810, an mRNA therapeutic candidate targeting Ornithine Transcarbamylase Deficiency, utilizing LUNAR lipid-mediated delivery to enhance protein expression.
- Preclinical pipeline including various mRNA-based therapeutic and vaccine candidates targeting infectious diseases and rare disorders.
Arcturus Therapeutics executive team
- Joseph E. PayneFounder, President, CEO & Director
- Padmanabh ChivukulaFounder, Chief Scientific Officer, COO & Secretary
- Joseph RobertsPrincipal Accounting Officer & Controller
- Lance KurataChief Legal Officer
- Dennis M. MulroyChief Financial Officer
- Neda SafarzadehVice President and Head of IR/PR & Marketing
- Natasha O. BowmanChief Human Resources Officer
- Kevin T. SkolChief Business Officer
- Igor SmolenovChief Development Officer
- Ye ZhangChief Regulatory & Quality Assurance Officer
Latest news about Arcturus Therapeutics
Key financials
Reported results for Arcturus Therapeutics, in USD.
- Market cap
- 313.5M
- Revenue (TTM)
- 29.4M
- P/E ratio
- —
- EPS (diluted, TTM)
- -3.3
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 67.2M | -75M | -65.8M | |
| 138.4M | -95.7M | -80.9M | |
| 157.7M | -78.2M | -29.7M | |
| 205.8M | 12.2M | 9.3M |